Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · Real-Time Price · USD

1.190

-0.050 (-4.03%)

At close: Jul 23, 2025, 4:00 PM

1.160

-0.030 (-2.52%)

After-hours: Jul 23, 2025, 5:31 PM EDT

Oncolytics Biotech Employees

Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.

Employees

28

Change

-1

Growth

-3.45%

Revenue / Employee

n/a

Profits / Employee

-$782,765

Market Cap

118.34M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	28	-1	-3.45%
Dec 31, 2022	29	3	11.54%
Dec 31, 2021	26	1	4.00%
Dec 31, 2020	25	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ONCY News

8 hours ago - Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential - PRNewsWire
1 day ago - Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules - PRNewsWire
7 days ago - Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types - PRNewsWire
13 days ago - Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers - PRNewsWire
15 days ago - Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies - PRNewsWire
23 days ago - Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy - PRNewsWire
6 weeks ago - Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs - PRNewsWire
2 months ago - Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - PRNewsWire